Non-steroidal anti-inflammatory drugs and gastroprotection with proton pump inhibitors: A focus on ketoprofen/omeprazole

Clinical Drug Investigation

Volumn 32, Issue 4, 2012, Pages 221-233

  Gigante, Antonio ^a   Tagarro, Ignacio ^b  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b Meda Pharmaceuticals   (Spain)

Author keywords

Fixed combinations; Gastrointestinal ulcer; Ketoprofen; Ketoprofen omeprazole; Nonsteroidal anti inflammatories; Omeprazole; Proton pump inhibitors

Indexed keywords

ACECLOFENAC; AXORID; DICLOFENAC; ESOMEPRAZOLE PLUS NAPROXEN; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOPROFEN PLUS OMEPRAZOLE; KETOPROFEN PLUS SUCRALFATE; MISOPROSTOL; MISOPROSTOL PLUS NAPROXEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PHENYLBUTAZONE; PIROXICAM; PIRPROFEN; RANITIDINE; SULINDAC; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANKYLOSING SPONDYLITIS; BIOEQUIVALENCE; DIARRHEA; DIGESTIVE SYSTEM INJURY; DIGESTIVE SYSTEM ULCER; DRUG CAPSULE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; GASTRODUODENAL ULCER; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HIGH RISK PATIENT; HUMAN; INCIDENCE; MONOTHERAPY; NONHUMAN; OSTEOARTHRITIS; PATIENT COMPLIANCE; PEPTIC ULCER BLEEDING; PRIORITY JOURNAL; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SINGLE DRUG DOSE; STOMACH DISEASE; STOMACH PROTECTION; SYMPTOM; VERTEBRA FRACTURE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DRUG COMBINATIONS; GASTROINTESTINAL DISEASES; HUMANS; KETOPROFEN; MEDICATION ADHERENCE; OMEPRAZOLE; PROTON PUMP INHIBITORS; RISK FACTORS;

EID: 84858066393     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11596670-000000000-00000     Document Type: Review

References (110)

1. Singh G. Gastrointestinal complications of prescription and over-the-counter nonsteroidal anti-inflammatory drugs: a view from the ARAMIS database. Arthritis, Rheumatism, and Aging Medical Information System. Am J Ther 2000 Mar; 7 (2): 115-21
2. Naesdal J, Brown K. NSAID-associated adverse effects and acid control aids to prevent them: a review of current treatment options. Drug Saf 2006; 29 (2): 119-32 (Pubitemid 43213886)
3. Becker JC, Domschke W, Pohle T. Current approaches to prevent NSAID-induced gastropathy: COX selectivity and beyond. Br J Clin Pharmacol 2004 Dec; 58 (6): 587-600 (Pubitemid 39665146)
4. Singh G, Rosen Ramey D. NSAID induced gastrointestinal complications: the ARAMIS perspective - 1997. Arthritis, Rheumatism, and Aging Medical Information System. J Rheumatol Suppl. 1998 May; 51: 8-16 (Pubitemid 28210537)
5. Straus WL, Ofman JJ, MacLean C, et al. Do NSAIDs cause dyspepsia? A meta-analysis evaluating alternative dyspepsia definitions. Am J Gastroenterol 2002 Aug; 97 (8): 1951-8
6. Laine L. Nonsteroidal anti-inflammatory drug gastropathy. Gastrointest Endosc Clin N Am 1996 Jul; 6 (3): 489-504 (Pubitemid 26237732)
7. Vonkeman HE, Fernandes RW, van de Laar MA. Underutilization of gastroprotective drugs in patients with NSAID-related ulcers. Int J Clin Pharmacol Ther 2007 May; 45 (5): 281-8 (Pubitemid 46739098)
8. Sturkenboom MC, Burke TA, Dieleman JP, et al. Underutilization of preventive strategies in patients receiving NSAIDs. Rheumatology (Oxford) 2003 Nov; 42 Suppl. 3: iii23-31 (Pubitemid 37407011)
9. Clinard F, Bardou M, Sgro C, et al. Non-steroidal antiinflammatory and cytoprotective drug co-prescription in general practice: a general practitioner-based survey in France. Eur J Clin Pharmacol 2001 Dec; 57 (10): 737-43 (Pubitemid 34031267)
10. Abraham NS, El-Serag HB, Johnson ML, et al. National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs. Gastroenterology 2005 Oct; 129 (4): 1171-8 (Pubitemid 41446857)
11. Moore RA, Derry S, Phillips CJ, et al. Nonsteroidal antiinflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice. BMC Musculoskelet Disord 2006; 7: 79
12. Suh DC, Hunsche E, Shin HC, et al. Co-prescribing of proton pump inhibitors among chronic users of NSAIDs in the UK. Rheumatology (Oxford) 2008 Apr; 47 (4): 458-63
13. Goldstein JL, Howard KB, Walton SM, et al. Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications. Clin Gastroenterol Hepatol 2006 Nov; 4 (11): 1337-45
14. Sturkenboom MC, Burke TA, Tangelder MJ, et al. Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2003 Dec; 18 (11-12): 1137-47 (Pubitemid 38021600)
15. Abraham NS, Hartman C, Castillo D, et al. Effectiveness of national provider prescription of PPI gastroprotection among elderly NSAID users. Am J Gastroenterol 2008 Feb; 103 (2): 323-32 (Pubitemid 351248716)
16. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med 1991 Nov 15; 115 (10): 787-96
17. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal antiinflammatory drugs: a randomized, double-blind, placebocontrolled trial. Ann Intern Med 1995 Aug 15; 123 (4): 241-9
18. Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994 Mar 26; 343 (8900): 769-72 (Pubitemid 24098698)
19. Lanas A, Ferrandez A. Inappropriate prevention of NSAID-induced gastrointestinal events among long-term users in the elderly. Drugs Aging 2007; 24 (2): 121-31 (Pubitemid 46327571)
20. Lewis SC, Langman MJ, Laporte JR, et al. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol 2002 Sep; 54 (3): 320-6
21. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000 Nov 23; 343 (21): 1520-8
22. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal antiinflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study. A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000 Sep 13; 284 (10): 1247-55
23. Langman MJ, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994 Apr 30; 343 (8905): 1075-8
24. La Corte R, Caselli M, Castellino G, et al. Prophylaxis and treatment of NSAID-induced gastroduodenal disorders. Drug Saf 1999 Jun; 20 (6): 527-43 (Pubitemid 29296598)
25. Piper JM,RayWA, Daugherty JR, et al.Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann InternMed 1991 May 1; 114 (9): 735-40
26. Targownik LE, Thomson PA. Gastroprotective strategies among NSAID users: guidelines for appropriate use in chronic illness. Can Fam Physician 2006 Sep; 52 (9): 1100-5 (Pubitemid 44553332)
27. Vonkeman HE, van de Laar MA. Nonsteroidal antiinflammatory drugs: adverse effects and their prevention. Semin Arthritis Rheum 2010 Feb; 39 (4): 294-312
28. Sievert W, Stern AI, Lambert JR, et al. Low-dose antacids and nonsteroidal anti-inflammatory drug-induced gastropathy in humans. J Clin Gastroenterol 1991; 13 (Suppl. 1): S145-8
29. Singh G, Ramey DR, Morfeld D, et al. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis: a prospective observational cohort study. Arch Intern Med 1996 Jul 22; 156 (14): 1530-6
30. Agrawal NM, Roth S, Graham DY, et al. Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer: a randomized, controlled trial. Ann Intern Med 1991 Aug 1; 115 (3): 195-200
31. Stiel D, Ellard KT, Hills LJ, et al. Protective effect of enprostil against aspirin-induced gastroduodenal mucosal injury in man: comparison with cimetidine and sucralfate. Am J Med 1986 Aug 18; 81 (2A): 54-8 (Pubitemid 16013731)
32. French PC, Darekar BS,Mills JG, et al. Ranitidine in the prevention of non-steroidal anti-inflammatory drug-associated gastric and duodenal ulceration in arthritic patients. European J Gastroenterol Hepatol 1994; 6 (12): 1141-7 (Pubitemid 24351877)
33. Ehsanullah RS, Page MC, Tildesley G, et al. Prevention of gastroduodenal damage induced by non-steroidal antiinflammatory drugs: controlled trial of ranitidine. BMJ 1988 Oct 22; 297 (6655): 1017-21
34. Robinson M, Mills RJ, Euler AR. Ranitidine prevents duodenal ulcers associated with non-steroidal antiinflammatory drug therapy. Aliment Pharmacol Ther 1991 Apr; 5 (2): 143-50
35. Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 1996 May 30; 334 (22): 1435-9 (Pubitemid 26157439)
36. Bardhan KD, Bjarnason I, Scott DL, et al. The prevention and healing of acute non-steroidal anti-inflammatory drug-associated gastroduodenal mucosal damage by misoprostol. Br J Rheumatol 1993 Nov; 32 (11): 990-5 (Pubitemid 23334900)
37. Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet 1988 Dec 3; 2 (8623): 1277-80
38. Graham DY, White RH, Moreland LW, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Misoprostol Study Group. Ann Intern Med 1993 Aug 15; 119 (4): 257-62 (Pubitemid 23319880)
39. Ekstrom P, Carling L, Wetterhus S, et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal antiinflammatory drug therapy: a Nordic multicentre study. Scand J Gastroenterol 1996 Aug; 31 (8): 753-8 (Pubitemid 26255041)
40. Bianchi Porro G, Lazzaroni M, Petrillo M, et al. Prevention of gastroduodenal damage with omeprazole in patients receiving continuous NSAIDs treatment: a double blind placebo controlled study. Ital J Gastroenterol Hepatol 1998 Feb; 30 (1): 43-7
41. Scheiman JM, Yeomans ND, Talley NJ, et al. Prevention of ulcers by esomeprazole in at-risk patients using nonselective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 2006 Apr; 101 (4): 701-10
42. Pilotto A, Franceschi M, Leandro G, et al. Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/nonsteroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2004 Nov 15; 20 (10): 1091-7 (Pubitemid 39657942)
43. Cullen D, Bardhan KD, Eisner M, et al. Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment Pharmacol Ther 1998 Feb; 12 (2): 135-40 (Pubitemid 28059980)
44. Hawkey CJ. Progress in prophylaxis against nonsteroidal anti-inflammatory drug-associated ulcers and erosions. Omeprazole NSAID Steering Committee. AmJ Med 1998 Mar 30; 104 (3A): 67S-74S; discussion 9S-80S
45. Desai JC, Sanyal SM, Goo T, et al. Primary prevention of adverse gastroduodenal effects from short-term use of non-steroidal anti-inflammatory drugs by omeprazole 20 mg in healthy subjects: a randomized, double-blind, placebo-controlled study. Dig Dis Sci 2008 Aug; 53 (8): 2059-65
46. Bianchi Porro G, Imbesi V, Lazzaroni M. Pantoprazole vs placebo in prevention of NSAID-induced ulcers [abstract]. Gastroenterology 1998; 114: A74
47. Graham DY, Agrawal NM, Campbell DR, et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med 2002 Jan 28; 162 (2): 169-75 (Pubitemid 34098186)
48. Lanas A, Rodrigo L, Marquez JL, et al. Low frequency of upper gastrointestinal complications in a cohort of highrisk patients taking low-dose aspirin or NSAIDS and omeprazole. Scand J Gastroenterol 2003 Jul; 38 (7): 693-700 (Pubitemid 36920489)
49. Hoer A, Gothe H, Schiffhorst G, et al. Comparison of the effects of diclofenac or other non-steroidal antiinflammatory drugs (NSAIDs) and diclofenac or other NSAIDs in combination with proton pump inhibitors (PPIs) on hospitalisation due to peptic ulcer disease. Pharmacoepidemiol Drug Saf 2007 Aug; 16 (8): 854-8 (Pubitemid 47322584)
50. Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol 2007 Mar; 102 (3): 507-15 (Pubitemid 46328156)
51. Vonkeman HE, Fernandes RW, van der Palen J, et al. Proton-pump inhibitors are associated with a reduced risk for bleeding and perforated gastroduodenal ulcers attributable to non-steroidal anti-inflammatory drugs: a nested case-control study. Arthritis Res Ther 2007; 9 (3): R52
52. Jordan KM, Arden NK, Doherty M, et al. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis. Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003 Dec; 62 (12): 1145-55 (Pubitemid 37500619)
53. ZhangW,Doherty M, ArdenN, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005 May; 64 (5): 669-81 (Pubitemid 40559291)
54. Zhang W, Doherty M, Leeb BF, et al. EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007 Mar; 66 (3): 377-88 (Pubitemid 46579641)
55. National Collaborating Centre for Chronic Conditions. Osteoarthritis: national clinical guideline for care and management in adults. 2008 [online]. Available from: http:// www.nice.org.uk/nicemedia/pdf/CG059FullGuideline.pdf [Accessed 2009 Jul 13]
56. No authors listed. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000 Sep; 43 (9): 1905-15
57. Luqmani R, Hennell S, Estrach C, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years). Rheumatology (Oxford) 2009 Apr; 48 (4): 436-9
58. No authors listed. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002 Feb; 46 (2): 328-46
59. Bardou M, Vauzelle-Kervroedan F. Proton pump inhibition (PPI) significantly reduces gastrointestinal (GI) events associated with the highly ulcerogenic NSAID, ketoprofen: a French prescription survey. Marseille: Congress of the FrenchAssociation of Pharmacology and Therapeutics, 2009
60. Davis R, Yarker YE, Goa KL. Diclofenac/misoprostol: a review of its pharmacology and therapeutic efficacy in painful inflammatory conditions. Drugs Aging 1995 Nov; 7 (5): 372-93
61. Geis GS. Overall safety of Arthrotec. Scand J Rheumatol Suppl. 1992; 96: 33-6
62. Kiff PS, Stead H, Morant SV, et al. Arthrotec, diclofenac and ibuprofen in general practice. Eur J Rheumatol Inflamm 1994; 14 (3 Suppl.): 31-8
63. Melo Gomes JA, Roth SH, Zeeh J, et al. Double-blind comparison of efficacy and gastroduodenal safety of diclofenac/ misoprostol, piroxicam, and naproxen in the treatment of osteoarthritis. Ann Rheum Dis 1993 Dec; 52 (12): 881-5 (Pubitemid 24019145)
64. Meda. Axorid: summary of product characteristics. 2010 [online]. Available from URL: http://www.medicines.org. uk/emc/medicine/22656/SPC/ Axorid+modified-release+ capsules/ [Accessed 2010 Nov 8]
65. Hochberg MC. NSAIDS: mechanisms and pathways of action. Hosp Pract (Off Ed) 1989 Mar 15; 24 (3): 185-90, 95, 98
66. Kantor TG. Ketoprofen: a review of its pharmacologic and clinical properties. Pharmacotherapy 1986 May-Jun; 6 (3): 93-103 (Pubitemid 16003473)
67. Veys EM. 20 years' experience with ketoprofen. Scand J Rheumatol Suppl. 1991; 90: 1-44
68. Williams RL, Upton RA. The clinical pharmacology of ketoprofen. J Clin Pharmacol 1988 Dec; 28 (12 Suppl.): S13-22
69. Folco G, Borghi C, Berti F. Non-steroidal antiinflammatory drug therapy: advantages and disadvantages of long halflife drugs versus slow-release formulations. Int J Clin Pharmacol Res 1986; 6 (6): 475-80 (Pubitemid 17213192)
70. Morley KD, Bernstein RM, Hughes GR, et al. A comparative trial of a controlled-release formulation of ketoprofen ('Oruvail') and a conventional capsule formulation of ketoprofen ('Orudis') in patients with osteoarthritis of the hip. Curr Med Res Opin 1984; 9 (1): 28-34 (Pubitemid 14134582)
71. Dreiser RL, Riebenfeld D. Nimesulide in the treatment of osteoarthritis: double-blind studies in comparison with piroxicam, ketoprofen and placebo.Drugs 1993; 46 Suppl. 1: 191-5 (Pubitemid 23324650)
72. Leopold M. A double-blind cross-over comparative study of ketoprofen versus naproxen in the treatment of osteoarthritis of the knee [abstract]. Scand J Gastroenterol 1980; 33: 45
73. Hossain MA. Comparison of the efficacy and tolerability of ketoprofen (Oruvail) 200 mg once daily with indomethacin (Indocid R) 75 mg twice daily in osteoarthritis of the knee and hip: a double-blind, within-patient, randomized trial. Clinical Trial Journal 1990; 27: 268-77
74. Gyory AN, Bloch M, Burry HC, et al. Orudis in management of rheumatoid arthritis and osteoarthrosis of the hip: comparison with indomethacin. Br Med J 1972 Nov 18; 4 (5837): 398-400
75. Bresnihan FP, Grahame R, Burry HC. Ketoprofen in the management of osteoarthrosis of the hip: comparison with phenylbutazone.RheumatolRehabil 1974Aug; 13 (3): 125-31
76. Cardoe N. Double-blind cross-over study of ketoprofen and phenylbutazone in patients with chronic osteoarthrosis of the hip. Rheumatol Rehabil 1976; Suppl: 27-33 (Pubitemid 8015443)
77. Lang E, Steger W. A comparative study of efficacy and tolerability of ketoprofen and piroxicam [abstract]. Br J Clin Pract 1981 Jul-Aug; 35 (7-8): 267
78. Bendix T, Schmidt I, Rasmussen K, et al. Diclofenac (Voltaren) and ketoprofen (Orudis) in rheumatoid arthritis: a randomized double-blind multicentre trial. Curr Ther Res 1983; 33: 192-9 (Pubitemid 13145236)
79. Boey ML, Rae S, Feng PH. Comparison of efficacy of and tolerance to ketoprofen and diclofenac sodium in the treatment of rheumatoid arthritis. Singapore Med J 1988 Jun; 29 (3): 240-5 (Pubitemid 19030345)
80. Wollheim FA, Lindroth Y, Sjoblom KG. A comparison of ketoprofen and naproxen in rheumatoid arthritis. Rheumatol Rehabil 1978 Suppl.: 78-83 (Pubitemid 9092405)
81. Martin-Mola E, Gijon-Banos J, Ansoleaga JJ. Aceclofenac in comparison to ketoprofen in the treatment of rheumatoid arthritis. Rheumatol Int 1995; 15 (3): 111-6
82. Jalava S, Junnila SYT. Double-blind cross-over study of piroxicam (Felden) and ketoprofen (Orudis) in rheumatoid arthritis. Scand J Rheumatol 1986; 16: 68-9
83. El-Ghobarey AF, Rennie JA, Hadidi T, et al. A comparative trial of large doses of ketoprofen and indomethacin in the treatment of rheumatoid arthritis. Curr Med Res Opin 1976; 4 (6): 432-5
84. Fossgreen J, Kirchheiner B, Petersen FO, et al. Clinical evaluation of ketoprofen (19.583 R.P.) in rheumatoid arthritis: double-blind cross-over comparison with indomethacin. Scand J Rheumatol Suppl. 1976; 1976 (0): 93-8
85. Uddenfeldt P, Leden I,Rubin B.A double-blind comparison of oral ketoprofen 'controlled release' and indomethacin suppository in the treatment of rheumatoid arthritis with special regard to morning stiffness and pain on awakening. Curr Med Res Opin 1993; 13 (3): 127-32 (Pubitemid 23256074)
86. Peltola P. A double-blind cross-over study of ketoprofen and phenylbutazone in rheumatoid arthritis. Scand J Rheumatol 1976 Suppl.; 14: 111-3
87. Vignon E, Courcier S, Laborde C, et al. LP 200 mg flurbiprofen versus LP 200 mg ketoprofen in rheumatoid arthritis in rheumatologic practice. Rev Rhum Ed Fr 1993 Jul-Sep; 60 (7-8): 530-5
88. Mills SB, Bloch M, Bruckner FE. Double-blind cross-over study of ketoprofen and ibuprofen in management of rheumatoid arthritis. Br Med J 1973 Oct 13; 4 (5884): 82-4
89. Montrone F, Fumagalli M, Pellegrini P, et al. A doubleblind cross-over evaluation of ketoprofen (Orudis) and ibuprofen in the management of rheumatoid arthritis. Rheumatol Rehabil 1979 May; 18 (2): 114-8 (Pubitemid 9194864)
90. Calin A, Bennett RM, Sukhupunyaraksa S, et al. Doubleblind, multi-centre parallel trial of ketoprofen and ibuprofen in the treatment of rheumatoid arthritis. J Rheumatol 1977; 4 (2): 153-7
91. Saxena RP, Saxena U. A comparative trial of ketoprofen and ibuprofen in patients with rheumatic disease. Curr Med Res Opin 1978; 5 (6): 484-8 (Pubitemid 8365510)
92. Ahern MJ, Wetherall M, Leslie A, et al. A comparison of ketoprofen SR and sulindac in the elderly with rheumatoid arthritis. Br J Clin Pract 1992; 46 (4): 229-33 (Pubitemid 23048696)
93. Jessop JD. Double-blind study of ketoprofen and phenylbutazone in ankylosing spondylitis. Rheumatol Rehabil 1976 Suppl.: 37-42 (Pubitemid 8015445)
94. Treadwell BL, Tweed JM. Ketoprofen (Orudis) in ankylosing spondylitis. N ZMed J 1975May 14; 81 (539): 411-3
95. Renier JC, Fournier M, Loyau G, et al. Ankylosing spondylitis: comparative trial of two non-steroidal antiinflammatory agents - pirprofen and ketoprofen. Nouv Presse Med 1982 Aug 28; 11 (33): 2494-6 (Pubitemid 12046867)
96. Toft B, Christophersen J, Christensen N, et al.A double-blind, crossover study of a sustained-release tablet of ketoprofen and normal ketoprofen capsules in the treatment of patients with osteoarthritis. Curr Med Res Opin 1985; 9 (10): 708-12 (Pubitemid 16203077)
97. Teule M. Double-blind comparative multicenter study of the efficacy and safety of a slow-release tablet of 200 mg ketoprofen and a 50mg ketoprofen capsule four times daily. Curr Ther Res 1986; 40: 1129-46 (Pubitemid 17224836)
98. Caldwell JR, Germain BF, Lourie SH, et al. Ketoprofen versus indomethacin in patients with rheumatoid arthritis: a multicenter double blind comparative study. J Rheumatol 1988 Oct; 15 (10): 1476-9 (Pubitemid 18263093)
99. Schumacher Jr HR. Ketoprofen extended-release capsules: a new formulation for the treatment of osteoarthritis and rheumatoid arthritis. Clin Ther 1994Mar-Apr; 16 (2): 145-59 (Pubitemid 24321651)
100. AstraZeneca. Losec capsules 10 mg, 20 mg and 40 mg: summary of Product Characteristics. 2008
101. Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors: focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 1996 Jul; 31 (1): 9-28 (Pubitemid 26238200)
102. Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) study group. N Engl J Med 1998 Mar 12; 338 (11): 727-34 (Pubitemid 28115091)
103. Yeomans ND, Tulassay Z, Juhasz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versusOmeprazole forNSAID-associatedUlcer Treatment (ASTRONAUT) study group. N Engl J Med 1998 Mar 12; 338 (11): 719-26
104. Moore A, Bjarnason I, Cryer B, et al. Evidence for endoscopic ulcers as meaningful surrogate endpoint for clinically significant upper gastrointestinal harm. Clin Gastroenterol Hepatol 2009 Nov; 7 (11): 1156-63
105. Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001 Mar 29; 344 (13): 967-73 (Pubitemid 32240315)
106. Targownik LE, Metge CJ, Leung S, et al. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs. Gastroenterology 2008 Apr; 134 (4): 937-44
107. Garcia Rodriguez LA, Ruigomez A. Secondary prevention of upper gastrointestinal bleeding associated with maintenance acid-suppressing treatment in patients with peptic ulcer bleed. Epidemiology 1999 May; 10 (3): 228-32 (Pubitemid 29187754)
108. Laine L, Curtis SP, Cryer B, et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2007 Feb 10; 369 (9560): 465-73 (Pubitemid 46217814)
109. Ethypharm. Data on file: clinical study report KEO/25004/ 001, 2006
110. Ethypharm. Data on file: clinical study report KEO/25004/ 002, 2008